Peter Attia MDOptimizing brain health: Alzheimer's risk factors, APOE, & prevention strategies [AMA 46 sneak peek]
At a glance
WHAT IT’S REALLY ABOUT
Alzheimer's Diagnosis, APOE Genetics, and Whether Healthy Habits Offset Genetic Risk
- Alzheimer's is diagnosed clinically through symptoms, cognitive testing, and ruling out other causes, with definitive confirmation only at autopsy, though blood biomarkers and amyloid PET are improving certainty.
- Attia describes the C2N plasma amyloid test as promising but early, and he reserves it for patients at highest risk because low pretest probability would reduce its predictive value.
- Three rare deterministic genes account for about 1% of cases, while APOE4 is present in about 25% of the population and in roughly two-thirds of Alzheimer's cases without being deterministic.
- Women have about twice the global prevalence of Alzheimer's as men, which Attia interprets as roughly 20% higher risk per decade combined with women living longer.
- Epidemiologic data from the Chicago Health and Aging Project suggest that healthy lifestyle behaviors offset much of the added risk in E4 carriers, though the data are observational and confounded.
IDEAS WORTH REMEMBERING
5 ideasAlzheimer's has no neat, single diagnostic test.
Diagnosis starts with clinical assessment and exclusion of other causes like hypothyroidism or B12 and B6 deficiencies, with definitive confirmation only at autopsy. Biomarkers and PET can make a skilled diagnostician nearly certain.
There is no Alzheimer's equivalent of APOB.
Attia says Alzheimer's is more complicated and lacks a simple, population-validated marker. He is comfortable checking APOB in everyone but not the C2N test.
Test usefulness depends on who is tested.
Applying the C2N test broadly would lower positive and negative predictive value, so Attia uses it only in people with the highest pretest probability, in about six or seven patients.
APOE4 is a strong risk factor but not destiny.
About 25% of people carry at least one E4 copy and they make up two-thirds of cases, yet many E4 carriers never develop dementia, including some centenarians. Modifier genes such as Klotho KLVS can bring risk back toward that of a 3-3.
Comprehensive Alzheimer's genetic testing is still hard.
There is no turnkey way to assess the full set of relevant genes, so Attia's practice works with Richard Isaacson's team to go through whole genome sequences, which he prefers to shorter SNP tests like 23andMe.
WORDS WORTH SAVING
5 quotesThat 25% of the population makes up two-thirds of all cases of Alzheimer's disease.
— Peter Attia
I don't know that this would matter a whole heck of a lot unless you believed you could do something about it.
— Peter Attia
In other words, this suggests that you, you have some control over this. This is malleable.
— Peter Attia
The lift that you can get with healthy behaviors seems to be even greater as an E4 than as an E3.
— Peter Attia
If you applied the C2N test willy-nilly across everybody, my fear is you would probably get a lot of noise and you would-- I mean, I don't-- this isn't a- an arbitrary fear. It's just mathematics.
— Peter Attia
High quality AI-generated summary created from speaker-labeled transcript.
